- |||||||||| alvocidib (DSP-2033) / Sumitomo Pharma
Journal: Therapeutic potential of flavopiridol in diabetic retinopathy: Targeting DDX58. (Pubmed Central) - Jul 10, 2024 Notably, our research demonstrated that flavopiridol modulates the DDX58/NLRP3 signaling pathway, thereby exerting its therapeutic effects in suppressing inflammation and neovascularization in DR. This study unveils groundbreaking therapeutic agents and innovative targets for DR, and establishes a progressive theoretical framework for the application of ubiquitin-related therapies in DR.
- |||||||||| Mekinist (trametinib) / Novartis, BeiGene, Keytruda (pembrolizumab) / Merck (MSD), Tafinlar (dabrafenib) / Novartis, BeiGene
Review, Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Promising Therapeutic Targets for Recurrent/Metastatic Anaplastic Thyroid Cancer. (Pubmed Central) - Jul 10, 2024 The off-label utilization of "precision medicine" combinations imposes a considerable financial strain, underscoring the necessity for further clinical trials to elucidate promising therapeutic avenues for this orphan disease. There is a pressing need for the development and support of clinical trials investigating genomically driven and immune-based therapies for anaplastic thyroid cancer.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS
Journal: Immunotherapy for patients with thyroid cancer: a comprehensive appraisal. (Pubmed Central) - Jul 10, 2024 Additionally, other approaches like dendritic cell vaccination and radioimmunotherapy have been explored mainly for MTC, showing potential but requiring further investigation. While immunotherapy holds promise, especially in combination with other treatments, further research, and high-quality clinical trials are necessary to establish its effectiveness in treating advanced thyroid cancers.
- |||||||||| Yescarta (axicabtagene ciloleucel) / Gilead
Journal, CAR T-Cell Therapy: Toxic epidermal necrolysis-like cutaneous toxicity following chimeric antigen receptor T-cell therapy in recurrent large B-cell lymphoma. (Pubmed Central) - Jul 10, 2024 We present a case of a 69-year-old man with diffuse large B-cell lymphoma treated with axicabtagene-ciloleucel CAR-T therapy, who developed a rare and severe cutaneous toxicity resembling toxic epidermal necrolysis (TEN)...Notably, allopurinol-induced TEN was considered with the patient's recent exposure to allopurinol, although the onset and minimal mucosal involvement did not align with typical presentations of allopurinol-induced cases...This case expands the spectrum of CAR-T therapy-related cutaneous toxicities, highlighting the need for early recognition of histopathology and tailored management by dermatologists. Further understanding of these reactions is crucial for optimizing the safety profile of this groundbreaking immunotherapy.
- |||||||||| dordaviprone (ONC201) / Chimerix, Tecentriq (atezolizumab) / Roche
Trial completion date: ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer (clinicaltrials.gov) - Jul 10, 2024 P1, N=58, Recruiting, Further understanding of these reactions is crucial for optimizing the safety profile of this groundbreaking immunotherapy. Trial completion date: Jan 2025 --> Jul 2025
- |||||||||| EO2401 / Enterome
Trial completion date, Combination therapy, Checkpoint block, Metastases: Spencer: A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma (clinicaltrials.gov) - Jul 9, 2024 P1/2, N=70, Active, not recruiting, N=440 --> 49 | Trial completion date: Jul 2026 --> Jul 2024 | Active, not recruiting --> Terminated; Study terminated by sponsor. Trial completion date: Nov 2025 --> Oct 2024
- |||||||||| defactinib (VS-6063) / Verastem, Opdivo (nivolumab) / BMS, avutometinib (VS-6766) / Verastem
New P2 trial, Combination therapy, IO biomarker, Metastases: Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jul 9, 2024 P2, N=50, Not yet recruiting,
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, Trial initiation date, Combination therapy: Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL (clinicaltrials.gov) - Jul 9, 2024 P1, N=15, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Initiation date: Dec 2024 --> Jul 2024
- |||||||||| Imdelltra (tarlatamab-dlle) / Amgen
Journal: Tarlatamab (Imdelltra) for small cell lung cancer. (Pubmed Central) - Jul 9, 2024 Surgical conversion was feasible in a notable proportion of patients and associated with better survival outcomes. No abstract available
- |||||||||| nibrozetone (RRx-001) / EpicentRx
Journal: Dissociative Electron Attachment Dynamics of a Promising Cancer Drug Indicates Its Radiosensitizing Potential. (Pubmed Central) - Jul 9, 2024 2-Bromo-1-(3,3-dinitroazetidin-1-yl)ethan-1-one (RRx-001) is a hypoxic cell chemotherapeutics with already demonstrated synergism in combined chemo-radiation therapy...Based on our quantum chemical calculations, we propose that bidirectional intersystem crossing between ?*(NO2) and ?*(C-Br) states explains the experimental spectra. The fast dynamics monitored will impact the condensed phase chemistry of the anion as well.
- |||||||||| AiRuiKa (camrelizumab) / HLB Bio Group, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Journal, PD(L)-1 Biomarker: Prognostic Value of Alpha-Fetoprotein in Unresectable Hepatocellular Carcinoma Treated with Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Camrelizumab. (Pubmed Central) - Jul 9, 2024 Multivariate analysis results indicated that both early AFP response and AFP response independently predicted OS [hazard ratio (HR) 2.963, 95% confidence interval (CI) 1.333-6.585, p=0.008, and HR 6.182, 95% CI 1.780-21.466, p=0.004] and PFS (HR 2.186, 95% CI 1.107-4.318, p=0.024, and HR 3.078, 95% CI 1.407-6.730, p=0.005), serving as significant prognostic values. Early AFP response and AFP response serve as predictive biomarkers for the effectiveness of HAIC combined with lenvatinib and camrelizumab in patients with u-HCC.
- |||||||||| Rituxan (rituximab) / Roche
Journal: Elderly Male With Epstein-Barr Virus (EBV)-Induced Pure Red Cell Aplasia. (Pubmed Central) - Jul 9, 2024 Pure red cell aplasia (PRCA) is a rare hematologic disorder presenting with symptomatic normocytic anemia with preservation of other bone marrow cell lineages that may be acquired in adulthood due to malignancy, autoimmune disease, and infections. PRCA has been attributed to Epstein-Barr virus (EBV) in patients with underlying malignancy; however, we present a rare case of EBV-related PRCA in a previously healthy elderly male without an underlying malignancy who developed transfusion-dependent anemia that responded to glucocorticoids, rituximab, and intravenous immunoglobulins.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD)
Journal, Checkpoint inhibition, Checkpoint block: Immune Checkpoint Blockade in Melanoma - Earlier is Better? (Pubmed Central) - Jul 9, 2024 Neoadjuvant ICIs offer advantages like T cell expansion, early-stage efficacy, treatment assessment through surgical specimens, and potential tumor size reduction for better surgical outcomes. However, further research is needed to optimize patient selection and treatment protocols.
- |||||||||| Darzalex (daratumumab) / J&J
Enrollment closed, Trial completion date, Trial primary completion date: Steroid Sparing Treatment With in Newly Diagnosed Transplant Ineligible Patients With Multiple Myeloma (clinicaltrials.gov) - Jul 8, 2024 P2, N=28, Active, not recruiting, Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- |||||||||| Enweida (envafolimab) / 3DMed, Tracon Pharma, Ascletis
Retrospective data, Journal, Metastases: Efficacy and Safety of Neoadjuvant Subcutaneous Envafolimab in dMMR/MSI-H Locally Advanced Colon Cancer. (Pubmed Central) - Jul 8, 2024 This meta-analysis highlights the toxicity profiles of anti-angiogenic TKI monotherapies, and thus enables high-level recommendations for the choice of anti-angiogenic TKIs on the basis of the patient's age, ethnicity, comorbidities, and comedications, for personalized treatment. Envafolimab yielded promising surgical outcomes and safety in dMMR/MSI-H locally advanced colon cancer, representing a promising treatment modality for this population.
|